Searched for
LUPIN HEALTHCARE UK
Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...- Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned VitabioticsIndian drugmaker Lupin and private equity firms are exploring the acquisition of UK's Vitabiotics. The deal is valued at approximately one ...
- Lupin subsidiary inks pact to acquire Netherlands-based VISUfarmaLupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. Th...
- Stocks in news: Airtel, HDFC Bank, Macrotech Developers, Hindustan Copper, Hindustan ZincMarkets experience a significant recovery, buoyed by gains in major stocks such as Airtel, HDFC Bank, and Macrotech Developers. Key develop...
- Lupin acquires UK-based firm for 12.3 million poundsLupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to...
- Lupin's arm gets UK regulator nod for COPD treatmentGlobal pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the...
- Lupin launches Molnulup for COVID-19 treatmentMolnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...
- Stocks in the news: HDFC AMC, Bharti Airtel, Max Healthcare, Lupin and IndiGoLupin said it has launched Droxidopa capsules, used in treating orthostatic dizziness, in the US market.
- Lupin inks distribution pact with 3 firms to commercialise NaMuscla in EuropeExeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will commercialise NaMuscla for the symptomatic treatment of myotonia in adul...
- Aurobindo Pharma may buy Portugal's Generis, deal likely to be valued at $200 millionAurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by ri...
- India will be world power in pharma, says Jhunjhunwala; is it time to buy?Jhunjhunwala continues to bet on the pharma sector and Aurobindo Pharma is his preferred pick, which has rallied a little over 6 per cent i...
- Budget 2016: Pharma companies to benefit from push to patents but cut in tax sops for R&D criticizedLarge Indian and global drug makers are set to benefit from the budget announcement for a 10% tax rebate on earnings from global patent fil...
- 5 Pharma stocks that propelled BSE Healthcare to lifetime highDespite the concerns on import alerts from the USFDA and recent drug recalls, the pharma sector was one of the top performers in the last q...
- Indian generic drug makers like Lupin, Dr Reddy’s Laboratories, Sun Pharma eye Japanese marketIn April, Lupin formed a joint venture with Japan’s Yoshindo for biosimilars. It is also in talks with other local drug makers for alliance...
- Women hold just 5 pc board positions in BSE-100 firms: SurveyPortraying the stark gender imbalance in top corporate rungs, a study has found that women hold barely 5 per cent of board positions in the...
- Mid-cap pharma firms focus on LatAm marketLupin and Glenmark Pharmaceuticals are leading Indian mid-cap drug makers in exploiting rising demand for medicines in South American natio...
- Indian firms expect US FDA’s local office to speed up approvalsThe US Food and Drugs Administration’s new office in India could likely boost local pharma companies’ efforts to process their applications...
- Lupin allots shares to foreign fundsLupin Ltd says it has alloted 783,181 equity shares upon conversion of FCCBs worth $9.60 million to foreign funds.
- Wal-Mart may source Indian genericsHere’s the big break Indian pharma majors have been looking for in their global game. Raj Jain, Wal-Mart’s chief executive designate for In...
- Top 10 pharma cos post 57% increase in Q3 netBuoyed by overseas acquisitions, the Indian pharma sector has posted a good set of numbers for the third quarter ended December 31, 2006.
Load More
